{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 31 of 74', 'Concomitant medication assessment', 'Drug compliance assessment', 'Adverse event (AE) assessment', 'For those patients experiencing skin AEs, additional skin toxicity questionnaires', 'to be completed by the patient and clinician', 'ECOG and Karnofsky performance status', 'Physical examination, Weight & Blood Pressure', 'Haematology (WBC, differential ANC, Platelets, Hb)- Cycle 1, day 1 may be', 'omitted if screening haematology is done within 2 weeks.', 'Biochemistry (Urea, Na, K, GGT, ALT or AST, Total Bilirubin, Albumin, Total', 'Protein, Serum Creatinine, Creatinine Clearance, Serum Calcium, ALP, LDH)', 'Cycle 1, day 1 may be omitted if screening biochemistry is done within 2 weeks.', 'CT/MRI scans for reassessment of measureable disease using RECIST version', '1.1 (Cycle 2 Between days 8-15 only)', 'QoL questionnaires (Cycle 2 day 1 only)', 'ECHO (any time during Cycle 2 only)', 'Prescription and dispensing of treatment (Day 1 only)', 'Research blood sample (baseline sample must be taken before starting drug', 'treatment)', 'Pharmacokinetic research blood sampling (subset of patients only) on cycle 1', 'day 1, cycle 2 day 15- see Section 13 for details', '10.2.3', 'Cycles 3 and all subsequent cycles', 'The following assessments are to be performed on day 1 of all cycles after cycle 2*:', '(prior to drug treatment).', 'Concomitant medication assessment', 'Drug compliance assessment', 'AE assessment', 'For patients experiencing skin AEs, additional skin toxicity questionnaires to be', 'completed by the patient and clinician', 'ECOG and Karnofsky performance status', 'Physical Examination, Weight & Blood Pressure', 'Haematology (WBC, differential ANC, Platelets, Hb)', 'Biochemistry (Urea, Na, K, GGT, ALT or AST, Total Bilirubin, Albumin, Total', 'Protein, Serum Creatinine, Creatinine Clearance, Serum Calcium, ALP, LDH)', 'QoL questionnaires (every 12 calendar weeks)', 'CT/MRI for reassessment of measureable disease using RECIST version 1.1', '(every 8 calendar weeks ie. week 14, 22, 30 etc). Patients continuing treatment', 'beyond 52 weeks can have their scanning frequency reduced to 12 weekly.', 'ECHO (during cycle 5 and subsequently every 3 cycles ie. cycle 5, cycle 8, cycle', '11 etc. while on treatment)', 'Prescription and dispensing of treatment', 'Research blood sample, cycle 3, cycle 4 and every other cycle ie. cycles 6, 8, 10', 'etc while on treatment', 'Pharmacokinetic research blood sampling (subset of patients only) - see Section', '13 for timepoints.', '*If patients have been on treatment for more than 52 weeks, clinic visits can be every', 'other cycle, with telephone follow-up to ensure patient review is at least every 4 weeks', 'until progression.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 32 of 74', '10.2.4', 'End of Treatment visit', 'This visit can take place up to 30 days after treatment discontinuation.', 'Concomitant medication assessment', 'Compliance assessment', 'AE assessment', 'For patients experiencing skin AEs, additional skin toxicity questionnaires to be', 'completed by the patient and clinician', 'ECOG and Karnofsky performance status', 'Physical Examination, Weight & Blood Pressure', 'Haematology (WBC, differential ANC, Platelets, Hb)', 'Biochemistry (Urea, Na, K, GGT, ALT or AST, Total Bilirubin, Albumin, Total', 'Protein, Serum Creatinine, Creatinine Clearance, Serum Calcium, ALP, LDH)', '10.3 Disease Progression', 'At the time of the protocol-defined disease progression (no more than 7 days after) and', 'before further protocol treatment or any new treatment is initiated, the following', 'assessments are required:', 'Concomitant medication assessment', 'Compliance assessment', 'AE assessment', 'ECOG and Karnofsky performance status', 'Physical Examination, weight & Blood Pressure', 'Haematology (WBC, differential ANC, Platelets, Hb)', 'Biochemistry (Urea, Na, K, GGT, ALT or AST, Total Bilirubin, Albumin, Total', 'Protein, Creatinine Clearance, Serum Creatinine, Serum Calcium, ALP, LDH)', 'QoL questionnaires', 'CT/MRI for reassessment of measureable disease using RECIST version 1.1', 'Research blood sample', 'Pharmacokinetic research blood sampling (subset of patients only) - see Section', '13', 'In patients undergoing surgical resection or biopsy of a progressing lesion, a', 'tumour sample will be requested.', '10.4 Follow-up if stopping treatment prior to disease progression', 'Patients will be followed-up every 4 weeks (7 days) after stopping treatment* until', 'disease progression, as follows:', 'Physical examination, Weight & Blood Pressure', 'Concomitant medication assessment', 'ECOG and Karfnofsky performance status', 'QoL questionnaires (every 12 calendar weeks only)', 'CT/MRI for reassessment of measureable disease (every 8 calendar weeks)', '*If patients have been on treatment/follow-up for more than 52 weeks prior to disease', 'progression, follow-up visits can be every 8 weeks, with telephone follow-up to ensure', 'patient review is at least every 4 weeks until progression, and repeat imaging can be', 'reduced to 12 weekly.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}